| Code | CSB-RA005157MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US10081679, targeting CEACAM1 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1). CEACAM1 is a transmembrane glycoprotein that functions as a critical immune checkpoint regulator, modulating T cell activation and inflammatory responses. This protein plays important roles in immune homeostasis, angiogenesis, and cellular metabolism. CEACAM1 is implicated in various pathological conditions including cancer, where it can promote tumor immune evasion and metastasis, as well as metabolic disorders such as insulin resistance and non-alcoholic fatty liver disease.
The reference antibody patent US10081679 describes therapeutic applications targeting CEACAM1 for immune modulation and cancer treatment. This biosimilar antibody provides researchers with a valuable tool for investigating CEACAM1 biology, exploring its role in tumor-immune interactions, studying immune checkpoint mechanisms, and evaluating potential therapeutic interventions in oncology and immunometabolic research. The recombinant production ensures consistent quality and reproducibility for experimental studies.
There are currently no reviews for this product.